Discontinued — last reported Q1 '18
Allowance for Doubtful Accounts Receivable (Current)
ResMed Allowance for Doubtful Accounts Receivable (Current) increased by 0.9% to $29.47M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.7%, from $19.83M to $29.47M. Over 4 years (FY 2021 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -8.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
Detailed definition
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Peer comparison
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_currentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $32.14M | $29.92M | $28.22M | $24.41M | $23.26M | $23.87M | $27.12M | $24.85M | $23.60M | $20.53M | $21.82M | $19.81M | $21.13M | $23.60M | $20.67M | $19.83M | $22.42M | $24.61M | $29.21M | $29.47M |
| QoQ Change | — | -6.9% | -5.7% | -13.5% | -4.7% | +2.6% | +13.6% | -8.4% | -5.0% | -13.0% | +6.3% | -9.2% | +6.7% | +11.7% | -12.4% | -4.1% | +13.1% | +9.8% | +18.7% | +0.9% |
| YoY Change | — | — | — | — | -27.6% | -20.2% | -3.9% | +1.8% | +1.5% | -14.0% | -19.5% | -20.3% | -10.5% | +14.9% | -5.3% | +0.1% | +6.1% | +4.3% | +41.3% | +48.7% |
Allowance for Doubtful Accounts Receivable (Current) at Other Companies
Frequently Asked Questions
- What is ResMed's allowance for doubtful accounts receivable (current)?
- ResMed (RMD) reported allowance for doubtful accounts receivable (current) of $29.47M in Q1 2026.
- How has ResMed's allowance for doubtful accounts receivable (current) changed year-over-year?
- ResMed's allowance for doubtful accounts receivable (current) increased by 48.7% year-over-year, from $19.83M to $29.47M.
- What is the long-term trend for ResMed's allowance for doubtful accounts receivable (current)?
- Over 4 years (2021 to 2025), ResMed's allowance for doubtful accounts receivable (current) has grown at a -8.6% compound annual growth rate (CAGR), from $32.14M to $22.42M.
- What does allowance for doubtful accounts receivable (current) mean?
- The estimated portion of customer invoices that the company expects will never be paid.